Compare Sana Biotechnology Inc (SANA) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VNET Group Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while VNET Group Inc trades at $7.39 (market cap $2.14B). The key difference: VNET Group Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VNET | |
|---|---|---|
Market Cap | $1.13B | $2.14B |
Sector | Health | Technology |
52-Week High | $5.92 | $14.03 |
52-Week Low | $2.68 | $6.29 |
Enterprise Value | $1.05B | $5.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
VNET trades at $7.40, down 1.07% today, with a neutral technical signal and bearish moving averages. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt pose risks. Investment opportunity hinges on execution of capacity expansion and AI demand, while investors face volatility from earnings misses and competitive pressures in China's data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
